FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ian Stratford

Research Profile

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Roben G Gieling; Adrian L Harris; Catriona A Parker; Naomi Robertson; Ian J Stratford; Lisa A De Costa; Kaye J Williams
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Simon J Dovedi; Jamie Honeychurch; Monique H M Melis; Ian J Stratford; Robert W Wilkinson; Amy L Adlard; Timothy M Illidge
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
GE Adams; I R Flockhart; C E Smithen; Ian J Stratford; Peter Wardman; M E Watts
Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ian Stratford (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Roben G Gieling; Adrian L Harris; Catriona A Parker; Naomi Robertson; Ian J Stratford; Lisa A De Costa; Kaye J Williams
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Journal of enzyme inhibition and medicinal chemistry 2013;28(2):360-9.
2013: Simon J Dovedi; Jamie Honeychurch; Monique H M Melis; Ian J Stratford; Robert W Wilkinson; Amy L Adlard; Timothy M Illidge
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Blood 2013;121(2):251-9.
2012: GE Adams; I R Flockhart; C E Smithen; Ian J Stratford; Peter Wardman; M E Watts
Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.
Radiation research 2012;178(2):AV183-9.
2011: Mark S Dunstan; Matthew Humphries; David Leys; John Barnes; Richard A Bryce; Ian J Stratford; Roger C Whitehead; Karen A Nolan
Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.
Journal of medicinal chemistry 2011;54(19):6597-611.
2011: Joana M Senra; Brian A Telfer; Stephen R Wedge; Kim E Cherry; David G Hirst; Cian M McCrudden; Mark J O'Connor; Ian J Stratford
Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Molecular cancer therapeutics 2011;10(10):1949-58.
2011: Katherine Ann Scott; John Barnes; Roger C Whitehead; Ian J Stratford; Karen Ann Nolan
Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.
Biochemical pharmacology 2011;81(3):355-63.
2010: Karen A Nolan; Mary C Caraher; Matthew P Humphries; Hoda Abdel-Aal Bettley; Richard A Bryce; Ian J Stratford
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Bioorganic & medicinal chemistry letters 2010;20(24):7331-6.
2010: S J Lunt; Christopher Cawthorne; M Ali; Brian A Telfer; M Babur; A Smigova; Peter Julyan; Patricia M Price; Ian J Stratford; W D Bloomer; M V Papadopoulou; Kaye J Williams
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
British journal of cancer 2010;103(2):201-8.
2010: K A Nolan; M P Humphries; Richard A Bryce; Ian J Stratford
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.
Bioorganic & medicinal chemistry letters 2010;20(9):2832-6.
2010: Rupak Doshi; Philip Day; Paolo Carampin; Ewan Blanch; Ian J Stratford; Nicola Tirelli
Spectrophotometric analysis of nucleic acids: oxygenation-dependent hyperchromism of DNA.
Analytical and bioanalytical chemistry 2010;396(6):2331-9.
2010: Paula Sommer; Rachel L Cowen; Andrew Berry; Ann Cookson; Brian A Telfer; Kaye J Williams; Ian J Stratford; Paul Kay; Anne White; David W Ray
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth.
Endocrine-related cancer 2010;17(1):203-13.
2010: Karen A Nolan; Matthew P Humphries; John Barnes; Jeremy R Doncaster; Mary C Caraher; Nicola Tirelli; Richard A Bryce; Roger C Whitehead; Ian J Stratford
Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.
Bioorganic & medicinal chemistry 2010;18(2):696-706.
2010: Melissa K Friswell; Helen Gika; Ian J Stratford; Georgios Theodoridis; Brian Telfer; Ian D Wilson; Andrew J McBain
Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.
PloS one 2010;5(1):e8584.
2009: Kaye J Williams; Mark R Albertella; Brian Fitzpatrick; Paul M Loadman; Steven D Shnyder; Edwin C Chinje; Brian A Telfer; Chris R Dunk; Peter A Harris; Ian J Stratford
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
Molecular cancer therapeutics 2009;8(12):3266-75.
2009: Karen A Nolan; Jeremy R Doncaster; Mark S Dunstan; Katherine A Scott; A David Frenkel; David Siegel; David Ross; John Barnes; Colin Levy; David Leys; Roger C Whitehead; Ian J Stratford; Richard A Bryce
Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).
Journal of medicinal chemistry 2009;52(22):7142-56.
2009: Aoife Shannon; Brian A Telfer; Paul D Smith; Muhammed Babur; Armelle Logie; Robert W Wilkinson; Camille Debray; Ian J Stratford; Kaye J Williams; Stephen R Wedge
The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6619-29.
2009: D L Roberts; Kaye J Williams; Rachel L Cowen; M Barathova; A J Eustace; S Brittain-Dissont; Michael J Tilby; D Graham Pearson; C J Ottley; Ian J Stratford; Caroline Dive
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.
British journal of cancer 2009;101(8):1290-7.
2009: Simendra Singh; Rachel L Cowen; Edwin C Chinje; Ian J Stratford
The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells.
Radiation research 2009;171(5):572-80.
2009: Manal Mehibel; Simendra Singh; Edwin C Chinje; Rachel L Cowen; Ian J Stratford
Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
Molecular cancer therapeutics 2009;8(5):1261-9.
2008: G Xenaki; T Ontikatze; Ramkumar Rajendran; Ian J Stratford; Caroline Dive; Marija Krstic-Demonacos; Constantinos Demonacos
PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.
Oncogene 2008;27(44):5785-96.
2008: Kaye J Williams; Brian A Telfer; Aoife Shannon; M Babur; Ian J Stratford; Stephen R Wedge
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
The British journal of radiology 2008;81 Spec No 1():S21-7.
2008: Brian Fitzpatrick; Manal Mehibel; Rachel L Cowen; Ian J Stratford
iNOS as a therapeutic target for treatment of human tumors.
Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2008;19(2):217-24.
2008: Philip Reigan; Abdul Gbaj; Ian J Stratford; Richard A Bryce; Sally Freeman
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
European journal of medicinal chemistry 2008;43(6):1248-60.
2007: Karen A Nolan; He Zhao; Paul F Faulder; A David Frenkel; David J Timson; David Siegel; David Ross; Terrence R Burke; Ian J Stratford; Richard A Bryce
Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
Journal of medicinal chemistry 2007;50(25):6316-25.
2007: Milène Volpato; Nathalie Abou-Zeid; Richard W Tanner; Lee T Glassbrook; James Taylor; Ian J Stratford; Paul M Loadman; Mohammed Jaffar; Roger M Phillips
Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Molecular cancer therapeutics 2007;6(12 Pt 1):3122-30.
2007: Claire L Arthurs; James Raftery; Helen L Whitby; Roger C Whitehead; Natasha S Wind; Ian J Stratford
Arene cis-dihydrodiols: useful precursors for the preparation of analogues of the anti-tumour agent, 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC).
Bioorganic & medicinal chemistry letters 2007;17(21):5974-7.
2007: Christopher Cawthorne; Ric Swindell; Ian J Stratford; Caroline Dive; Arkadiusz Welman
Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model.
Journal of biomolecular techniques : JBT 2007;18(2):120-3.
2007: Virginia A McNally; Mehdi Rajabi; Abdul Gbaj; Ian J Stratford; Philip N Edwards; Kenneth T Douglas; Richard A Bryce; Mohammed Jaffar; Sally Freeman
Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase.
The Journal of pharmacy and pharmacology 2007;59(4):537-47.
2007: Kaye J Williams; Brian A Telfer; Aoife Shannon; Muhammad Babur; Ian J Stratford; Stephen R Wedge
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Molecular cancer therapeutics 2007;6(2):599-606.
2007: Claire L Arthurs; Natasha S Wind; Roger C Whitehead; Ian J Stratford
Analogues of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor properties.
Bioorganic & medicinal chemistry letters 2007;17(2):553-7.
2007: Melanie M L Green; Crispin T Hiley; Jonathan H Shanks; Ian C Bottomley; Catharine M L West; Richard A Cowan; Ian J Stratford
Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
International journal of radiation oncology, biology, physics 2007;67(1):84-90.
2006: Karen A Nolan; David J Timson; Ian J Stratford; Richard A Bryce
In silico identification and biochemical characterization of novel inhibitors of NQO1.
Bioorganic & medicinal chemistry letters 2006;16(24):6246-54.
2006: Louisa M Brown; Rachel L Cowen; Camille Debray; Amanda Eustace; Janine T Erler; Freda C D Sheppard; Catriona A Parker; Ian J Stratford; Kaye J Williams
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.
Molecular pharmacology 2006;69(2):411-8.
2006: P Kabuubi; Juliette A Loncaster; Susan E Davidson; Robin D Hunter; C Kobylecki; Ian J Stratford; Catharine M L West
No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.
British journal of cancer 2006;94(1):115-20.
2005: David S Riddick; Chunja Lee; Shairoz Ramji; Edwin C Chinje; Rachel L Cowen; Kaye J Williams; Adam Patterson; Ian J Stratford; Charles S Morrow; Alan J Townsend; Youssef Jounaidi; Chong-Sheng Chen; Ting Su; Hong Lu; Pamela S Schwartz; David J Waxman
Cancer chemotherapy and drug metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(8):1083-96.
2005: Catharine M L West; Michael McKay; Tobias Hoelscher; Michael Baumann; Ian J Stratford; Robert G Bristow; Mayumi Iwakawa; Takashi Imai; Surekha M Zingde; Mitchell S. Anscher; Jean Bourhis; Adrian C Begg; Karin Haustermans; Søren M Bentzen; Jolyon H Hendry
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.
International journal of radiation oncology, biology, physics 2005;62(5):1264-73.
2005: Sarah Jane Lunt; Brian A Telfer; Richard J Fitzmaurice; Ian J Stratford; Kaye J Williams
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4212-6.
2005: Rachel E Airley; Roger M Phillips; A E Evans; John A Double; Angelika Burger; H H Feibig; Catharine M L West; Ian J Stratford
Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts.
International journal of oncology 2005;26(6):1477-84.
2005: Naomi Chadderton; Rachel L Cowen; Freda C D Sheppard; Suzanne Robinson; Olga Greco; Simon D Scott; Ian J Stratford; Adam Patterson; Kaye J Williams
Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.
International journal of radiation oncology, biology, physics 2005;62(1):213-22.
2005: Arkadiusz Welman; Christopher Cawthorne; Jane Barraclough; Nigel Smith; Gareth J Griffiths; Rachel L Cowen; Judith C Williams; Ian J Stratford; Caroline Dive
Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression.
Journal of cellular biochemistry 2005;94(6):1148-62.
2005: Kaye J Williams; Brian A Telfer; Dia Xenaki; Mary R Sheridan; Isabelle Desbaillets; Hans J W Peters; Davina Honess; Adrian L Harris; Gabi U Dachs; Albert J van der Kogel; Ian J Stratford
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;75(1):89-98.
2005: M M L Green; G J Hutchison; Helen R Valentine; R J Fitzmaurice; Susan E Davidson; Robin D Hunter; Caroline Dive; Catharine M L West; Ian J Stratford
Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix.
British journal of cancer 2005;92(3):449-58.
2005: Philip Reigan; Philip N Edwards; Abdul Gbaj; Christian Cole; Simon T Barry; Ken M Page; Susan E Ashton; Richard W A Luke; Kenneth T Douglas; Ian J Stratford; Mohammed Jaffar; Richard A Bryce; Sally Freeman
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
Journal of medicinal chemistry 2005;48(2):392-402.
2004: Kaye J Williams; Brian A Telfer; Sandra Brave; Jane Kendrew; Lynsey Whittaker; Ian J Stratford; Stephen R Wedge
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8587-93.
2004: Gillian J Hutchison; Helen R Valentine; Juliette A Loncaster; Susan E Davidson; Robin D Hunter; Steve Roberts; Adrian L Harris; Ian J Stratford; Patricia M Price; Catharine M L West
Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8405-12.
2004: Roger M Phillips; Mohammed Jaffar; Derek J Maitland; Paul M Loadman; Steven D Shnyder; Gillian Steans; Patricia A Cooper; Amanda Race; Adam Patterson; Ian J Stratford
Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.
Biochemical pharmacology 2004;68(11):2107-16.
2004: Philip Reigan; Abdul Gbaj; Edwin C Chinje; Ian J Stratford; Kenneth T Douglas; Sally Freeman
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
Bioorganic & medicinal chemistry letters 2004;14(21):5247-50.
2004: Mohammed Jaffar; Nathalie Abou-Zeid; Li Bai; Ibrahim Mrema; Ian Robinson; Richard Tanner; Ian J Stratford
Quinone bioreductive prodrugs as delivery agents.
Current drug delivery 2004;1(4):345-50.
2004: Janine T Erler; Christopher Cawthorne; Kaye J Williams; Marianne Koritzinsky; Bradly G Wouters; Clare Wilson; Crispin Miller; Constantinos Demonacos; Ian J Stratford; Caroline Dive
Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.
Molecular and cellular biology 2004;24(7):2875-89.
2004: Joo-Young Kim; Catharine M L West; Helen R Valentine; Tim Ward; Adam Patterson; Ian J Stratford; Steve Roberts; Jolyon H Hendry
Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;70(3):311-7.
2004: Richard J Oliver; R T M Woodwards; Philip Sloan; Nalin Thakker; Ian J Stratford; Rachel E Airley
Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies.
European journal of cancer (Oxford, England : 1990) 2004;40(4):503-7.
2004: Rachel L Cowen; Kaye J Williams; Edwin C Chinje; Mohammed Jaffar; Freda C D Sheppard; Brian A Telfer; Natasha S Wind; Ian J Stratford
Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
Cancer research 2004;64(4):1396-402.
2004: Joo-Young Kim; Chul-Hwan Kim; Ian J Stratford; Adam Patterson; Jolyon H Hendry
The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line.
International journal of radiation oncology, biology, physics 2004;58(2):376-85.
2004: Kaye J Williams; Rachel L Cowen; Louisa M Brown; Edwin C Chinje; Mohammed Jaffar; Ian J Stratford
Hypoxia in tumors: molecular targets for anti-cancer therapeutics.
Advances in enzyme regulation 2004;44():93-108.
2004: Joo-Young Kim; Adam Patterson; Ian J Stratford; Jolyon H Hendry
The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Anti-cancer drugs 2004;15(1):71-7.
2003: Virginia A McNally; Abdul Gbaj; Kenneth T Douglas; Ian J Stratford; Mohammed Jaffar; Sally Freeman; Richard A Bryce
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
Bioorganic & medicinal chemistry letters 2003;13(21):3705-9.
2003: Claire L M Goodyer; Edwin C Chinje; Mohammed Jaffar; Ian J Stratford; Michael Threadgill
Time-dependence and preliminary SAR studies in inhibition of nitric oxide synthase isoforms by homologues of thiocitrulline.
Bioorganic & medicinal chemistry letters 2003;13(21):3679-80.
2003: Mohammed Jaffar; Roger M Phillips; Kaye J Williams; Ibrahim Mrema; Christian Cole; Natasha S Wind; Tim Ward; Ian J Stratford; Adam Patterson
3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
Biochemical pharmacology 2003;66(7):1199-206.
2003: Claire L M Goodyer; Edwin C Chinje; Mohammed Jaffar; Ian J Stratford; Michael Threadgill
Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase.
Bioorganic & medicinal chemistry 2003;11(19):4189-206.
2003: Rachel L Cowen; Adam Patterson; Brian A Telfer; Rachel E Airley; Steve Hobbs; Roger M Phillips; Mohammed Jaffar; Ian J Stratford; Kaye J Williams
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Molecular cancer therapeutics 2003;2(9):901-9.
2003: Edwin C Chinje; Rachel L Cowen; Jian Feng; Sanjeev P Sharma; Natasha S Wind; Adrian L Harris; Ian J Stratford
Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Molecular pharmacology 2003;63(6):1248-55.
2003: Rachel E Airley; Juliette A Loncaster; James Raleigh; Adrian L Harris; Susan E Davidson; Robin D Hunter; Catharine M L West; Ian J Stratford
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
International journal of cancer. Journal international du cancer 2003;104(1):85-91.
2003: Christian Cole; Philip Reigan; Abdul Gbaj; Philip N Edwards; Kenneth T Douglas; Ian J Stratford; Sally Freeman; Mohammed Jaffar
Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase.
Journal of medicinal chemistry 2003;46(2):207-9.
2003: Ian J Stratford; Kaye J Williams; Rachel L Cowen; Mohammed Jaffar
Combining bioreductive drugs and radiation for the treatment of solid tumors.
Seminars in radiation oncology 2003;13(1):42-52.
2002: Adam Patterson; Kaye J Williams; Rachel L Cowen; Mohammed Jaffar; Brian A Telfer; M Saunders; Rachel E Airley; D Honess; Albert J van der Kogel; C Roland Wolf; Ian J Stratford
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
Gene therapy 2002;9(14):946-54.
2002: Gisele Höpfl; Roland H Wenger; Urs Ziegler; Thomas Stallmach; Olivier Gardelle; Roger Achermann; Melanie Wergin; Barbara Kaser-Hotz; H Mark Saunders; Kaye J Williams; Ian J Stratford; Max Gassmann; Isabelle Desbaillets
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor.
Cancer research 2002;62(10):2962-70.
2002: Kaye J Williams; Brian A Telfer; Ian J Stratford; Stephen R Wedge
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.
British journal of cancer 2002;86(7):1157-61.
2002: Paul E Murray; Virginia A McNally; Stacey D Lockyer; Kaye J Williams; Ian J Stratford; Mohammed Jaffar; Sally Freeman
Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase.
Bioorganic & medicinal chemistry 2002;10(3):525-30.
2002: Kaye J Williams; Brian A Telfer; Rachel E Airley; Hans P W Peters; Mary R Sheridan; Albert J van der Kogel; Adrian L Harris; Ian J Stratford
A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis.
Oncogene 2002;21(2):282-90.
2002: Edwin C Chinje; Kaye J Williams; Brian A Telfer; P J Wood; Albert J van der Kogel; Ian J Stratford
17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.
British journal of cancer 2002;86(1):136-42.
2002: Virginia A McNally; Adam Patterson; Kaye J Williams; Rachel L Cowen; Ian J Stratford; Mohammed Jaffar
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.
Current pharmaceutical design 2002;8(15):1319-33.
2001: Mohammed Jaffar; Kaye J Williams; Ian J Stratford
Bioreductive and gene therapy approaches to hypoxic diseases.
Advanced drug delivery reviews 2001;53(2):217-28.
2001: Juliette A Loncaster; A L Harris; Susan E Davidson; John P Logue; Robin D Hunter; C C Wycoff; Jaromir Pastorek; P J Ratcliffe; Ian J Stratford; Catharine M L West
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Cancer research 2001;61(17):6394-9.
2001: Rachel E Airley; Juliette A Loncaster; S Davidson; M Bromley; Steve Roberts; A Patterson; R Hunter; Ian J Stratford; C West
Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):928-34.
2001: Kaye J Williams; Rachel L Cowen; Ian J Stratford
Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations.
Breast cancer research : BCR 2001;3(5):328-31.
2000: RA Cooper; Bernadette M Carrington; Juliette A Loncaster; Susan M Todd; Susan E Davidson; John P Logue; A D Luthra; Andrew P Jones; Ian J Stratford; Robin D Hunter; Catharine M L West
Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2000;57(1):53-9.
2000: Laurence H Patterson; Stephanie R McKeown; Ketan Chatrabhuj Ruparelia; John A Double; Michael C Bibby; S Cole; Ian J Stratford
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
British journal of cancer 2000;82(12):1984-90.
2000: Mark P Saunders; Mohammed Jaffar; Adam Patterson; J Nolan; Matthew A Naylor; Roger M Phillips; Adrian L Harris; Ian J Stratford
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.
Biochemical pharmacology 2000;59(8):993-6.
2000: Mark P Saunders; Adam Patterson; Edwin C Chinje; Adrian L Harris; Ian J Stratford
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
British journal of cancer 2000;82(3):651-6.
1999: Edwin C Chinje; Adam Patterson; Mark P Saunders; Stacey D Lockyer; Adrian L Harris; Ian J Stratford
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
British journal of cancer 1999;81(7):1127-33.
1999: Roger M Phillips; Matthew A Naylor; Mohammed Jaffar; Stephen W Doughty; Steven A Everett; A G Breen; Guzanfar A Choudry; Ian J Stratford
Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
Journal of medicinal chemistry 1999;42(20):4071-80.
1999: Christian Cole; DS Marks; Mohammed Jaffar; Ian J Stratford; Kenneth T Douglas; Sally Freeman
A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor.
Anti-cancer drug design 1999;14(5):411-20.
1999: S Ulhaq; Edwin C Chinje; Matthew A Naylor; Mohammed Jaffar; Ian J Stratford; Michael Threadgill
Heterocyclic analogues of L-citrulline as inhibitors of the isoforms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor.
Bioorganic & medicinal chemistry 1999;7(9):1787-96.
1999: A P Garner; Mark Paine; I Rodriguez-Crespo; Edwin C Chinje; Paul R. Ortiz de Montellano; Ian J Stratford; D G Tew; C Roland Wolf
Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Cancer research 1999;59(8):1929-34.
1999: Mohammed Jaffar; Steven A Everett; Matthew A Naylor; S G Moore; S Ulhaq; Kantilal B Patel; Michael R L Stratford; J Nolan; Peter Wardman; Ian J Stratford
Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.
Bioorganic & medicinal chemistry letters 1999;9(1):113-8.
1998: S Ulhaq; Edwin C Chinje; Matthew A Naylor; Mohammed Jaffar; Ian J Stratford; Michael Threadgill
S-2-amino-5-azolylpentanoic acids related to L-ornithine as inhibitors of the isoforms of nitric oxide synthase (NOS).
Bioorganic & medicinal chemistry 1998;6(11):2139-49.
1998: L Griffiths; Ian J Stratford
The influence of elevated levels of platelet-derived endothelial cell growth factor/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation.
International journal of radiation oncology, biology, physics 1998;42(4):877-83.
1998: Mohammed Jaffar; Matthew A Naylor; N Robertson; Ian J Stratford
Targeting hypoxia with a new generation of indolequinones.
Anti-cancer drug design 1998;13(6):593-609.
1998: Adam Patterson; Mark P Saunders; Edwin C Chinje; L H Patterson; Ian J Stratford
Enzymology of tirapazamine metabolism: a review.
Anti-cancer drug design 1998;13(6):541-73.
1998: Ian J Stratford; P Workman
Bioreductive drugs into the next millennium.
Anti-cancer drug design 1998;13(6):519-28.
1998: Matthew A Naylor; Elizabeth Swann; Steven A Everett; Mohammed Jaffar; J Nolan; N Robertson; Stacey D Lockyer; Kantilal B Patel; MF Dennis; Michael R L Stratford; Peter Wardman; GE Adams; Christopher J Moody; Ian J Stratford
Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.
Journal of medicinal chemistry 1998;41(15):2720-31.
1998: Adam Patterson; Denis C Talbot; Ian J Stratford; Adrian L Harris
Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Cancer research 1998;58(13):2737-40.
1998: Mohammed Jaffar; Matthew A Naylor; N Robertson; Stacey D Lockyer; Roger M Phillips; Steven A Everett; GE Adams; Ian J Stratford
5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Anti-cancer drug design 1998;13(2):105-23.
1997: Matthew A Naylor; Mohammed Jaffar; J Nolan; M A Stephens; S Butler; Kantilal B Patel; Steven A Everett; GE Adams; Ian J Stratford
2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.
Journal of medicinal chemistry 1997;40(15):2335-46.
1997: Edwin C Chinje; Ian J Stratford
Role of nitric oxide in growth of solid tumours: a balancing act.
Essays in biochemistry 1997;32():61-72.
1997: L Griffiths; Ian J Stratford
Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
British journal of cancer 1997;76(6):689-93.
1997: S A Butler; P J Wood; S Cole; C Williams; GE Adams; Ian J Stratford
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
British journal of cancer 1997;76(4):438-44.
1997: S Ulhaq; Matthew A Naylor; Edwin C Chinje; Michael Threadgill; Ian J Stratford
S-2-amino-5-(2-nitroimidazol-1-yl)pentanoic acid: a model for potential bioreductively activated prodrugs for inhibitors of nitric oxide synthase (NOS) activity.
Anti-cancer drug design 1997;12(1):61-5.
1996: H M Barham; R Inglis; Edwin C Chinje; Ian J Stratford
Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
British journal of cancer 1996;74(8):1188-93.
1996: P J Wood; J M Sansom; Ian J Stratford; GE Adams; Csaba Szabó; Christoph Thiemermann; JR Vane
Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.
The British journal of cancer. Supplement 1996;27():S177-80.
1996: Peter Wardman; K I Priyadarsini; MF Dennis; Steven A Everett; Matthew A Naylor; Kantilal B Patel; Ian J Stratford; Michael R L Stratford; M Tracy
Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.
The British journal of cancer. Supplement 1996;27():S70-4.
1996: S Houlbrook; Adrian L Harris; J Carmichael; Ian J Stratford
Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.
Anticancer research 1996;16(4A):1603-10.
1996: P J Wood; Michael R Horsman; A A Khalil; F Steinberg; C Streffer; Jens Overgaard; Ian J Stratford; GE Adams
A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
Acta oncologica (Stockholm, Sweden) 1996;35(8):989-94.
1996: Adrian L Harris; H Zhang; Amir Moghaddam; S Fox; P Scott; A Pattison; K Gatter; Ian J Stratford; Roy Bicknell
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Breast cancer research and treatment 1996;38(1):97-108.
1995: S Houlbrook; C M Addison; Sally L Davies; J Carmichael; Ian J Stratford; Adrian L Harris; Ian D Hickson
Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
British journal of cancer 1995;72(6):1454-61.
1995: Adam Patterson; H M Barham; Edwin C Chinje; GE Adams; Adrian L Harris; Ian J Stratford
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
British journal of cancer 1995;72(5):1144-50.
1995: Adam Patterson; H Zhang; Amir Moghaddam; Roy Bicknell; Denis C Talbot; Ian J Stratford; Adrian L Harris
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
British journal of cancer 1995;72(3):669-75.
1995: Matthew A Naylor; GE Adams; A Haigh; S Cole; T Jenner; N Robertson; D Siemann; M A Stephens; Ian J Stratford
Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.
Anti-cancer drugs 1995;6(2):259-69.
1995: Christopher J Moody; Elizabeth Swann; S Houlbrook; M A Stephens; Ian J Stratford
Synthesis and biological activity of thiazolylindolequinones, analogues of the natural product BE 10988.
Journal of medicinal chemistry 1995;38(6):1039-43.
1995: P J Wood; J M Sansom; K Newell; I F Tannock; Ian J Stratford
Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin.
International journal of cancer. Journal international du cancer 1995;60(2):264-8.
1994: P J Wood; J M Sansom; S A Butler; Ian J Stratford; S M Cole; Csaba Szabó; Christoph Thiemermann; GE Adams
Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.
Cancer research 1994;54(24):6458-63.
1994: A S Cotterill; Christopher J Moody; R J Mortimer; C L Norton; N O'Sullivan; M A Stephens; N R Stradiotto; Elizabeth Swann; Ian J Stratford
Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.
Journal of medicinal chemistry 1994;37(22):3834-43.
1994: J Kirk; S K Syed; Adrian L Harris; M Jarman; Basil D Roufogalis; Ian J Stratford; J Carmichael
Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.
Biochemical pharmacology 1994;48(2):277-85.
1994: J M Sansom; B Sutton; N Reeves; J K Bradley; P J Wood; J C Bremner; GE Adams; Ian J Stratford
Combination of photodynamic therapy (PDT) and melphalan in experimental tumors.
International journal of radiation oncology, biology, physics 1994;29(3):463-6.
1994: P J Wood; J M Sansom; Ian J Stratford; GE Adams; Csaba Szabó; Christoph Thiemermann; JR Vane
Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine.
International journal of radiation oncology, biology, physics 1994;29(3):443-7.
1994: J Kirk; J Carmichael; Ian J Stratford; Adrian L Harris
Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.
British journal of cancer 1994;69(6):988-94.
1994: J C Bremner; J K Bradley; Ian J Stratford; GE Adams
Magnetic resonance spectroscopic studies on 'real-time' changes in RIF-1 tumour metabolism and blood flow during and after photodynamic therapy.
British journal of cancer 1994;69(6):1083-7.
1994: Christopher J Moody; N O'Sullivan; Ian J Stratford; M A Stephens; P Workman; S M Bailey; A Lewis
Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.
Anti-cancer drugs 1994;5(3):367-72.
1994: Adam Patterson; N Robertson; S Houlbrook; M A Stephens; GE Adams; Adrian L Harris; Ian J Stratford; J Carmichael
The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
International journal of radiation oncology, biology, physics 1994;29(2):369-72.
1994: B M Sutton; N J Reeves; Matthew A Naylor; E M Fielden; S Cole; GE Adams; Ian J Stratford
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice.
International journal of radiation oncology, biology, physics 1994;29(2):339-44.
1994: Matthew A Naylor; B M Sutton; J Nolan; Peter O'Neill; E M Fielden; GE Adams; Ian J Stratford
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity.
International journal of radiation oncology, biology, physics 1994;29(2):333-7.
1994: J C Bremner; J K Bradley; GE Adams; Matthew A Naylor; J M Sansom; Ian J Stratford
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
International journal of radiation oncology, biology, physics 1994;29(2):329-32.
1994: R Kalra; J C Bremner; P J Wood; J Sansom; C J Counsell; Ian J Stratford; GE Adams
31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589C.
International journal of radiation oncology, biology, physics 1994;29(2):285-8.
1994: GE Adams; Ian J Stratford
Bioreductive drugs for cancer therapy: the search for tumor specificity.
International journal of radiation oncology, biology, physics 1994;29(2):231-8.
1994: N Robertson; A Haigh; GE Adams; Ian J Stratford
Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1013-9.
1994: Ian J Stratford; GE Adams; J C Bremner; S Cole; H S Edwards; N Robertson; P J Wood
Manipulation and exploitation of the tumour environment for therapeutic benefit.
International journal of radiation biology 1994;65(1):85-94.
1993: Matthew A Naylor; M A Stephens; J Nolan; B Sutton; J H Tocher; E M Fielden; GE Adams; Ian J Stratford
Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
Anti-cancer drug design 1993;8(6):439-61.
1993: R Kalra; A M Jones; J Kirk; G E Adams; Ian J Stratford
The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro.
International journal of cancer. Journal international du cancer 1993;54(4):650-5.
1993: J Kirk; S Houlbrook; N S Stuart; Ian J Stratford; Adrian L Harris; J Carmichael
Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.
British journal of cancer 1993;67(6):1189-95.
1993: J Kirk; S Houlbrook; N S Stuart; Ian J Stratford; Adrian L Harris; J Carmichael
Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1152-7.
1993: Matthew A Naylor; Michael Threadgill; H D Showalter; Ian J Stratford; M A Stephens; E M Fielden; GE Adams
Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
Drug design and discovery 1993;10(3):249-55.
1992: J C Bremner; GE Adams; J K Pearson; J M Sansom; Ian J Stratford; J Bedwell; Stephen G Bown; Alexander J MacRobert; D Phillips
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
British journal of cancer 1992;66(6):1070-6.
1992: Matthew A Naylor; Michael Threadgill; P Webb; Ian J Stratford; M A Stephens; E M Fielden; GE Adams
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
Journal of medicinal chemistry 1992;35(19):3573-8.
1992: N Robertson; Ian J Stratford; S Houlbrook; J Carmichael; GE Adams
The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
Biochemical pharmacology 1992;44(3):409-12.
1992: S Cole; Ian J Stratford; E M Fielden; GE Adams; Wilbur R Leopold; W Elliott; M Suto; Judith Leopold
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
International journal of radiation oncology, biology, physics 1992;22(3):545-8.
1992: P J Wood; Ian J Stratford; J M Sansom; B M Cattanach; R M Quinney; GE Adams
The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy.
International journal of radiation oncology, biology, physics 1992;22(3):473-6.
1992: GE Adams; J C Bremner; C J Counsell; Ian J Stratford; C Thomas; P J Wood
Magnetic resonance spectroscopy studies on experimental murine and human tumors: comparison of changes in phosphorus metabolism with induced changes in vascular volume.
International journal of radiation oncology, biology, physics 1992;22(3):467-71.
1992: GE Adams; Ian J Stratford; H S Edwards; J C Bremner; S Cole
Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
International journal of radiation oncology, biology, physics 1992;22(4):717-20.
1992: E M Fielden; GE Adams; S Cole; Matthew A Naylor; Peter O'Neill; M A Stephens; Ian J Stratford
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
International journal of radiation oncology, biology, physics 1992;22(4):707-11.
1992: C Thomas; C Counsell; J Sansom; P Wood; Ian J Stratford; G Adams
The perfluorocarbon emulsion PFOB: potential indicator of change in blood volume using fluorine-19 NMR spectroscopy.
EXS 1992;61():362-7.
1992: Ian J Stratford
Bioreductive drugs in cancer therapy.
BJR supplement / BIR 1992;24():128-36.
1992: GE Adams; J C Bremner; Ian J Stratford; P J Wood
Can 31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygenation status?
BJR supplement / BIR 1992;24():137-41.
1991: J C Bremner; C J Counsell; GE Adams; Ian J Stratford; P J Wood; J F Dunn; George K Radda
In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.
British journal of cancer 1991;64(5):862-6.
1991: Michael Threadgill; P Webb; Peter O'Neill; Matthew A Naylor; M A Stephens; Ian J Stratford; S Cole; GE Adams; E M Fielden
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
Journal of medicinal chemistry 1991;34(7):2112-20.
1991: S Cole; Ian J Stratford; J Bowler; J Nolan; Eric G Wright; Sally A Lorimore; GE Adams
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
International journal of radiation oncology, biology, physics 1991;21(2):387-95.
1991: Matthew A Naylor; M A Stephens; Ian J Stratford; A Keohane; Peter O'Neill; Michael Threadgill; P Webb; E M Fielden; GE Adams
Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers.
Anti-cancer drug design 1991;6(3):151-67.
1991: H S Edwards; J C Bremner; Ian J Stratford
Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.
International journal of radiation biology 1991;60(1-2):373-7.
1991: J C Bremner; C J Counsell; H S Edwards; Ian J Stratford; GE Adams; A B Nethersell; P Bedford
Monitoring metabolic responses after induction of hypoxia in the KHT tumour using 31P NMR spectroscopy.
International journal of radiation biology 1991;60(1-2):363-7.
1991: H S Edwards; J C Bremner; Ian J Stratford
Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid.
International journal of radiation biology 1991;59(2):419-32.
1991: GE Adams; Ian J Stratford; J C Bremner; H S Edwards; E M Fielden
Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;20 Suppl 1():85-91.
1990: S Cole; Ian J Stratford; GE Adams; E M Fielden; T C Jenkins
Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Radiation research 1990;124(1 Suppl):S38-43.
1990: T C Jenkins; Matthew A Naylor; Peter O'Neill; Michael Threadgill; S Cole; Ian J Stratford; GE Adams; E M Fielden; M J Suto; Michael A Stier
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
Journal of medicinal chemistry 1990;33(9):2603-10.
1990: Matthew A Naylor; M A Stephens; S Cole; Michael Threadgill; Ian J Stratford; Peter O'Neill; E M Fielden; GE Adams
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
Journal of medicinal chemistry 1990;33(9):2508-13.
1990: A Keohane; J Godden; Ian J Stratford; GE Adams
The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
British journal of cancer 1990;61(5):722-6.
1990: J C Bremner; Ian J Stratford; J Bowler; GE Adams
Bioreductive drugs and the selective induction of tumour hypoxia.
British journal of cancer 1990;61(5):717-21.
1989: S Cole; Ian J Stratford; GE Adams
Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
International journal of radiation biology 1989;56(5):587-91.
1989: GE Adams; Ian J Stratford; A B Nethersell; R D White
Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin.
International journal of radiation oncology, biology, physics 1989;16(5):1179-82.
1989: GE Adams; Ian J Stratford; J Godden; N Howells
Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents.
International journal of radiation oncology, biology, physics 1989;16(5):1137-9.
1989: Ian J Stratford; I D Hickson; C N Robson; M Stephens
Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.
International journal of radiation oncology, biology, physics 1989;16(5):1307-10.
1989: Ian J Stratford; M A Stephens
The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
International journal of radiation oncology, biology, physics 1989;16(4):973-6.
1989: Ian J Stratford; GE Adams; J Godden; N Howells
Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
International journal of radiation biology 1989;55(3):411-22.
1988: Ian J Stratford; GE Adams; J Godden; J Nolan; N Howells; N Timpson
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
British journal of cancer 1988;58(2):122-7.
1988: J Walling; Ian J Stratford; GE Adams; M A Stephens
Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
International journal of radiation biology and related studies in physics, chemistry, and medicine 1988;53(4):641-9.
1987: P O'Neill; T C Jenkins; Ian J Stratford; A R Silver; I Ahmed; S S McNeil; E M Fielden; GE Adams
Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage.
Anti-cancer drug design 1987;1(4):271-80.
1986: J M Walling; Ian J Stratford; GE Adams; A R Silver; I Ahmed; T C Jenkins; E M Fielden
Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
International journal of radiation oncology, biology, physics 1986;12(7):1083-6.
1986: I Ahmed; T C Jenkins; J M Walling; Ian J Stratford; P W Sheldon; GE Adams; E M Fielden
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
International journal of radiation oncology, biology, physics 1986;12(7):1079-81.
1986: Ian J Stratford; J M Walling; A R Silver
The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
British journal of cancer 1986;53(3):339-44.
1986: Ian J Stratford; P O'Neill; P W Sheldon; A R Silver; J M Walling; GE Adams
RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.
Biochemical pharmacology 1986;35(1):105-9.